

1 **Figure 1.** Neutralisation of living isolates of SARS-CoV-2 by convalescent sera from critical or mild
2 patients with COVID-19 and by vaccine-elicited sera from subjects having received two doses of the
3 BNT162b2 vaccine.

4 *: p-value <0.05; **: p-value <0.01; ***: p-value <0.001; ****: p-value <0.0001; ns: non-significant.

5 Each serum was tested in duplicate and the mean NAb was used for the analysis. Titres were
6 transformed into \log_2 values for the calculation of mean NAb titres (a value of 0.5 was attributed by
7 convention to negative samples). In panels A, B and C: dotted lines represent the detection threshold
8 of 50% plaque reduction neutralisation test (PRNT₅₀) ≥ 20 for neutralising antibody (NAb) titres; full
9 lines represent median NAb titres and dash-dotted lines represent the 25% and 75% quartiles.

10 (A) Violin plot presenting the neutralisation of 2 SARS-CoV-2 isolates belonging to the 19A and 20B
11 clades by serum specimens obtained from subjects tested 6-months post mild COVID-19 (n=19) and
12 critical patients (n=15); the Wilcoxon matched-pair signed rank test was used for comparisons.

13 (B) Violin plot presenting the neutralisation of a SARS-CoV-2 isolate belonging to the 19A clade by
14 serum specimens obtained from vaccinated subjects (n=30), 6-months post mild COVID-19 subjects
15 (n=29) and critical patients (n=25); the Kruskal-Wallis test followed by Dunn's multiple comparison test
16 was used for comparisons.

17 (C) Violin plots presenting the neutralisation of 3 SARS-CoV-2 isolates belonging to the 19A,
18 20I/501Y.V1 and 20H/501Y.V2 clades by the same serum specimens than in (B); the Friedman test
19 followed by Dunn's multiple comparison test was used for comparisons.

20 (D) Capacity of neutralisation of the two tested VOC (20I/501Y.V1 and 20H/501Y.V2 clades) by the
21 same serum specimens as that in (B) and (C) in comparison to a 19A isolate taken as reference; the
22 Wilcoxon matched-pair signed rank test was used for comparisons.